GB201110390D0 - Compounds for use in stabilising p53 mutants - Google Patents

Compounds for use in stabilising p53 mutants

Info

Publication number
GB201110390D0
GB201110390D0 GB201110390A GB201110390A GB201110390D0 GB 201110390 D0 GB201110390 D0 GB 201110390D0 GB 201110390 A GB201110390 A GB 201110390A GB 201110390 A GB201110390 A GB 201110390A GB 201110390 D0 GB201110390 D0 GB 201110390D0
Authority
GB
United Kingdom
Prior art keywords
compounds
formula
stabilising
mutants
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201110390A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GB201110390A priority Critical patent/GB201110390D0/en
Publication of GB201110390D0 publication Critical patent/GB201110390D0/en
Priority to PCT/GB2012/051428 priority patent/WO2012175962A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided are compounds for use in a method of treatment of a subject who has a lesion or a tumour in which p53 carries a Y220C mutation, in which the compound is selected from compounds of the following formula (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof: (I) R: where A is CR4 or N; -R-1 is selected from -OH, -OMe, -NH2, -SH, -F and -CF3; -R2 is selected from -CI, -Br, -I, and ethynyl (-C=CH); -R3 is selected from -I, -Br, -CI, ethynyl (-C=CH), -R35, -H, -OMe, and -N02; wherein -R3S is selected from: and -R5 is selected from -COOH and: 8A formula Ilia formula 1Mb formula 111 o 3 where -R6, -R7A, - R7B, -Rs, and -R8A are as defined in the specification. Compounds of formula (I) are also provided, as is their use in methods of treatment, and methods for their preparation.
GB201110390A 2011-06-20 2011-06-20 Compounds for use in stabilising p53 mutants Ceased GB201110390D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201110390A GB201110390D0 (en) 2011-06-20 2011-06-20 Compounds for use in stabilising p53 mutants
PCT/GB2012/051428 WO2012175962A1 (en) 2011-06-20 2012-06-20 COMPOUNDS FOR USE IN STABILISING p53 MUTANTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201110390A GB201110390D0 (en) 2011-06-20 2011-06-20 Compounds for use in stabilising p53 mutants

Publications (1)

Publication Number Publication Date
GB201110390D0 true GB201110390D0 (en) 2011-08-03

Family

ID=44454323

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201110390A Ceased GB201110390D0 (en) 2011-06-20 2011-06-20 Compounds for use in stabilising p53 mutants

Country Status (2)

Country Link
GB (1) GB201110390D0 (en)
WO (1) WO2012175962A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101623985B1 (en) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stitched polypeptides
JP2013535514A (en) 2010-08-13 2013-09-12 エイルロン セラピューティクス，インコーポレイテッド Peptidomimetic macrocycle
JP6342808B2 (en) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド Peptidomimetic macrocycle
BR112014020103A2 (en) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. peptidomimetic macrocycles
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (en) 2012-11-01 2019-12-17 Aileron Therapeutics Inc disubstituted amino acids and their methods of preparation and use
CN107106642B (en) 2014-09-24 2021-02-26 艾瑞朗医疗公司 Peptidomimetic macrocycles and formulations thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10729671B2 (en) 2015-01-27 2020-08-04 Rutgers, The State University Of New Jersey Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer
WO2016123253A1 (en) 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey Hydrazne derivatives for the treatment of cancer
US10604480B2 (en) * 2015-01-27 2020-03-31 Rutgers, The State University Of New Jersey (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer
US10221133B2 (en) 2015-01-27 2019-03-05 Rutgers, The State University Of New Jersey (Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancer
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
BR112018016890A2 (en) 2016-02-19 2019-02-12 Pmv Pharmaceuticals, Inc. Methods and compounds to restore mutant p53 function
KR20220070255A (en) 2019-09-23 2022-05-30 피엠브이 파마슈티컬스 인코포레이티드 Methods and compounds for restoring mutant p53 function
US20230049952A1 (en) * 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
WO2021262484A1 (en) 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
JP2023533446A (en) * 2020-06-24 2023-08-03 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド A Companion Diagnostic Tool for Mutant P53 Reactivating Compounds
US11963953B2 (en) 2022-01-27 2024-04-23 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1273394B (en) 1965-08-21 1968-07-18 Dynamit Nobel Ag Weather explosives with high deflagration protection and energy
ES2002438A6 (en) * 1986-12-01 1988-08-01 Servicios Y Suministros Farmac Cyclohexyl-benzylamine deriv. prepn.
GB0808282D0 (en) * 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CZ302711B6 (en) * 2009-06-03 2011-09-14 Univerzita Palackého v Olomouci Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and pharmaceutical compositions comprising thereof

Also Published As

Publication number Publication date
WO2012175962A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
GB201110390D0 (en) Compounds for use in stabilising p53 mutants
TW200726739A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
CY1119177T1 (en) Arylmethoxy derivative of isoindoline and the compositions comprising these and methods of their use
WO2007092364A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
CY1115426T1 (en) 1,3-DIMUNATED IMIMAZOLIDIN-2-ONE PRODUCERS AS INPUTS TOY CYP 17
WO2014008458A3 (en) N-substituted benzamides and methods of use thereof
MX2017005663A (en) Substituted tetrahydropyrans and method of use.
MEP23808A (en) Pyridine[3,4-b]pyrazinones
IN2014DN09352A (en)
EA201490357A1 (en) INTRODUCTION
IN2014DN09348A (en)
MX2013010511A (en) Tricyclic gyrase inhibitors.
RS52949B (en) Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors
EA201390163A1 (en) HETEROBICYCLIC DERIVATIVES AS HCV INHIBITORS
MY180618A (en) Pyridazinone compounds and their use as daao inhibitors
MX2016016528A (en) Phosphatidylinositol 3-kinase inhibitors.
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
CY1118541T1 (en) D2 EXCLUSIVELY, COMPOSITION METHODS AND METHODS OF USE
PH12015500063B1 (en) Azaindole derivatives which act as pi3k inhibitors
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
MX2013005833A (en) Novel fused pyridine compounds as casein kinase inhibitors.
MX2010001486A (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists.
WO2007075749A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NI200900183A (en) PYRID [2,3-D] PYRIMIDINE - 7 - ONA COMPOUNDS AS PI3K - ALPHA INHIBITORS FOR THE TREATMENT OF CANCER.
MX2010005714A (en) Pyridine compounds.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)